Drug intelligence / Profile preview

AG2304R

Development stage: Unknown
Lead developer: AHN-GOOK PHARMACEUTICAL
Modality: Small Molecules

Overview

**AG2304R** is an investigational lipid-lowering drug product developed by Ahn-Gook Pharmaceutical for **primary hypercholesterolemia**. It served as the active-comparator intervention in a multicenter, randomized, double-blind Phase 3 study comparing AG2304R with AG2304T in adults with primary hypercholesterolemia. Public trial records confirm the program and indication, but do not disclose AG2304R's active ingredient composition, molecular target, dosage form, or specific mechanism of action.

Beyond the preview

Go deeper on AG2304R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AG2304R.

Explore the full profile